Introduction
Hypertension is the most prevalent cardiovascular risk factor in the population and in patients with established cardiovascular disease. [1] [2] [3] [4] Cardiovascular risk stratification of patients with hypertension should be made according to blood pressure, cardiovascular risk factors, target organ damage (TOD) and established cardiovascular or renal disease. 1, 5 TOD detection is strongly encouraged in current guidelines of European Society of Hypertension and European Society of Cardiology 1 because of its clinical impact on pharmacological treatment selection and prognostic value.
Left ventricle hypertrophy has been outlined as one the most specific TODs associated with hypertension, 1, 6, 7 has an elevated predictive value for cardiovascular events [7] [8] [9] and is modifiable with blood pressure control. 10, 11 Additionally, extracardiac TOD has gained increasing interest in last decades because of the identification of the increased risk associated with its presence. Glomerular filtration rate [12] [13] [14] and pathological ankle-brachial index (ABI) [15] [16] [17] are strongly recommended in current European Society of Hypertension and European Society of Cardiology guidelines because they are widely accessible and have clinical relevancy. Nevertheless, the impact of cardiac and non-cardiac TOD clustering in hypertensive patients with established cardiovascular disease has not been clearly defined. Moreover, the equivalency, synergism or superiority of these TODs has not been assessed in secondary prevention. The objective of the present study was to evaluate the prognostic value of TOD presence and clustering in patients with hypertension and established cardiovascular disease, concretely after an acute coronary syndrome (ACS).
Materials and methods
The Prevalencia de Afectació n de Miembros Inferiores en el paciente con Síndrome Coronario Agudo registry is an observational, prospective and multicentre study designed to investigate the prevalence of peripheral arterial disease (PAD) in patients admitted to Spanish hospitals with a diagnosis of ACS. A detailed description of the method used in the Prevalencia de Afectación de Miembros Inferiores en el paciente con Síndrome Coronario Agudo register has been published previously. 18, 19 In brief, patients X40 years admitted with an ACS (with or without ST-segment elevation ) were systematically screened with the ABI previous to hospital discharge to investigate the presence of peripheral arterial disease. A total of 1410 patients were included in the basal study and 13 died before hospital discharge. Investigators were then invited to follow up the 1397 remaining patients for 1 year. A total of 23 investigators comprising 241 patients declined the invitation; therefore, the prospective phase of the study included 1156 patients; 1054 (91.2%) of these fulfilled the complete follow-up. The protocol and the informed consent that was obtained from all patients were approved by an ethics committee.
Clinical evaluation and diagnosis of TOD Risk factors and cardiovascular antecedents of patients were collected following a standard questionnaire. Blood pressure was registered as the average of two measurements obtained after 10 min of physical resting, with mercury column sphygmomanometer. Patients were considered as hypertensive, if blood pressure was X140 or 90 mm Hg or were previously treated with specific medications. 1, 5 Left ventricular hypertrophy (LVH) was diagnosed by electrocardiogram according to the Cornell criteria when the sum of R-aVL and S-V3 was X28 mm (X20 in women) or the Sokolow-Lyon voltage (438 mm).
1 Glomerular filtration rate was estimated by Modification of Diet in Renal Disease Study equation 20 and values o60 ml per min per 1.73m 2 were considered as glomerular filtration rate impaired. 1, 14 Pathological ABI was considered for values o0.9 or 41.4. 21, 22 Determination of the ABI of both limbs was obtained between the third and seventh days of the ischaemic episode using a pocket Doppler BIDOP ES-100V3 (Vitalsys Health Care, Brussels, Belgium) and a blood pressure cuff, as previously described. 22 In brief, systolic blood pressure was measured in both arms and both ankles (posterior tibial artery) with the patient in the supine position. The ABI of each leg was calculated by dividing the systolic pressure of the right and left ankles by the greater systolic pressure of both arms, and the lowest ABI value was selected. Each participant hospital received identical Doppler equipment and specific training for measuring ABI to ensure the accuracy and consistency of the measurements.
End points
Patients were followed up for 12 months after hospital discharge to ascertain the occurrence of clinical events. Clinical complications were defined by the registry investigators' committee and collected in the data questionnaire. The primary end point was mortality (cardiovascular and non-cardiovascular deaths). Secondary end points were: hospital admission for non-fatal acute myocardial infarction (AMI), defined as elevation of serum markers of myocardial damage associated with chest pain or dynamic changes in ECG, hospitalization for heart failure, angina, coronary revascularization or stroke. A combined end point of ischaemic events (rehospitalization for angina, non-fatal AMI or coronary revascularization) was also assessed. All cardiovascular end points were confirmed by hospital reports. Every case of death reported by the medical staff was certified by the investigator of each hospital (death certificates or hospital records at the time of death, or direct contact with family of patients). The follow-up was done by medical visits or telephone calls.
Statistical analysis
Data were processed with SPSS 15.0. software (SPSS Inc., Chicago, IL, USA). Quantitative variables are presented as mean (s.d.). A w 2 test was used to analyse possible differences in clinical features between subgroups. Survival analysis were performed by Cox regression models by forward conditional inclusion of variables that obtained P-values o0.1 in the univariate analysis. Adjusted odds ratios (ORs) and corresponding confidence intervals (CIs) for secondary end points were obtained by multivariate logistic regression. Categorical variables' combinations (TOD and hypertension) were assessed by dummies. Statistical difference was accepted at Po0.05.
Results
Hypertensive patients accounted for 80% of the 1054 consecutive patients with ACS included and, as reflected in Table 1 , had slightly higher mean age, higher prevalence of risk factors and Target organ damage after acute coronary syndromes A Cordero et al previous cardiovascular disease. The presence of previous cardiovascular disease or TOD was higher in hypertensive patients. Patients with the antecedent of hypertension received more medical treatments at hospital discharge, especially angiotensin-converter enzyme inhibitors, angiotensin-receptor blockers and calcium-channel blockers (Table 2) .
During follow-up, mean time 387.9 (7.2) days and median 382 (364.0-430.0) days, a total of 59 (5.6%) deaths occurred. Mortality rate tended to be higher in hypertensive patients (6.1% versus 3.5%; P ¼ 0.16). Univariate and adjusted odds ratio, adjusted by age, gender, revascularization and medical treatments by Cox regression analysis adjusted by age, gender, type of ACS and medical treatments, are presented in Table 3 . When assessed globally, the presence of at least one TOD predicted mortality only in patients with hypertension and mortality rates' differences appeared very early in the followup (Figure 1) . A significant increase in mortality was observed in the clustering of TOD: 2.0%, if any TOD was present, 7.6% in one TOD, 11.1% in two TODs and 20.0%, if three TODs were present ( Figure 2 ). We also assessed the possible combinations of TOD and respective mortality rates, and observed that the joint presence of pathological ABI and renal dysfunction (RD) was the combination of two TODs with higher mortality rate ( Figure 3) . Multivariate analysis, adjusted by age, gender, type of ACS and medical treatments, of main cardiovascular secondary end points are presented in Table 4 . No variable showed higher risk of non-fatal AMI through the follow-up. Hypertension with and without TOD obtained significantly higher risk for recurrent angina or rehospitalization for heart failure, but not for non-fatal AMI. Age, previous AMI and previous heart failure were independently associated with rehospitalization for heart failure; coronary revascularization during hospitalization conferred a reduced risk of heart failure throughout the follow-up. An increased risk in the combined end point of angina, non-fatal AMI or repeat revascularization was observed in hypertensive patients without TOD (OR: 3.18; 95% CI: 1.31-7.70; P ¼ 0.01) and was still higher in patients with hypertension and TOD (OR: 4.61; 95% CI: 1.90-11.80; Po0.01). Abbreviations: ACEI, angiotensin-convertor enzyme inhibitor; ARB, angiotensin-receptor blocker; CCB, calcium-channel blocker, HT, hypertension; TOD, target organ damage.
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Discussion
The main results of our study are that TOD, and especially TOD clustering, predicts mortality and major cardiovascular events in hypertensive patients after an ACS. Pathological ABI was the TOD that conferred higher risk of death and its association with other TOD increased largely the rate of mortality. As the most prevalent risk factor in primary and secondary preventions of cardiovascular disease, risk stratification of patients with hypertension has a critical role in daily practice. 1 The Prevalencia de Afectació n de Miembros Inferiores en el paciente con Síndrome Coronario Agudo registry has previously reported that pathological ABI is present in around half of the ACS patients and it predicts hospital complications 18 specially in the subset of patients with hypertension; 19 Figure 1 Survival rate in patients with and without hypertension, according to the presence or absence of target organ damage (TOD). Target organ damage after acute coronary syndromes A Cordero et al moreover, we also demonstrated that subclinical PAD, detected by pathological ABI in absence of clinical symptoms, also has an increased risk of mortality. 23 In this new analysis, we aimed to analyse more precisely the impact of TOD on prognosis during the first year after an ACS; our results confirmed the critical role of pathological ABI but also highlighted the impact of TOD presence and clustering in hypertensive patients.
The prevalence of LHV, 7,24 pathological ABI 15, 25, 26 or impaired glomerular filtration rate 13, 27 is similar to other cohorts of patients with established cardiovascular disease. Although these are currently accepted as major TODs of hypertension, the role of TOD clustering on patients with established cardiovascular disease has not been clearly defined. Additionally, cardiac and non-cardiac hypertensionderived TOD might be explained by different mechanisms. Hypertension-derived LHV has been clearly related to volume and pressure overload induced by high blood pressure that eventually promote the activation of many cellular and systemic pathways implied in cardiovascular disease. 28, 29 Moreover, a worst prognosis has been attributed to ischemia-induced LVH compared with hypertension-induced LVH in animal models. 30 The increase in left ventricle mass drives to increased oxygen demand that can eventually lead to myocardial ischemia; in addition, LVH has been clearly associated with worst coronary flow reserve that predisposes to more ischaemic events. 31 Conversely, pathological ABI and RD seem to be directly derived from the endothelial dysfunction and atherosclerosis promoted by hypertension. 1 This could explain our results that found that pathological ABI was the only TOD that conferred an independently higher risk of mortality after an atherothrombotic event, an ACS, and was higher when it appeared Target organ damage after acute coronary syndromes A Cordero et al concomitantly with RD. Additionally, the presence of any TOD was more prevalent in hypertensive patients and conferred an increased risk of mortality only in them, which might reflect the specificity of high-blood pressure in their promotion. A progressive increased rate of mortality was observed with the clustering of TOD that increased from 2.0% in those without any TOD to 20% in patients with three TODs. Hypertension has systemic effects, and TOD can appear in several locations, if blood pressure is not accurately controlled. Therefore, there is a clear linear relationship between blood pressure values and left ventricular mass 32 that also correlates with cardiovascular risk. 7, 32, 33 Nevertheless, increasing values of blood pressure promote TOD systemically and, therefore, the prevalence of RD and peripheral arterial disease might increase in parallel. For example, the Cardiovascular Health Study identified poor blood pressure control as a risk factor for ABI decline over 6 year follow-up. 34 A cross-sectional registry performed in our country, the VIIDA Study, 24 demonstrated that hypertensive patients with LVH and non-controlled blood pressure had higher prevalence of peripheral arterial disease. More recently, the RICAR registry 27 outlined that patients with hypertension and RD have higher prevalence of LVH, cardiovascular disease and atrial fibrillation. The results of the Dallas Heart Study highlighted that there is a linear correlation between left ventricular mass and coronary artery calcium, a marker of coronary atherosclerosis. 29 Moreover, a recent pooled analysis of seven clinical trials that evaluated predictors of coronary plaque regression identified increasing blood pressure as an independent risk factor for plaque progression. 35 Our results demonstrate that the clustering of three widely available TODs in hypertensive patients after an ACS has a high predictive value for mortality in the first year after hospital discharge. The lack of predictive value of TOD in the total cohort could reflect the high specificity of this hypertensioninduced vascular damage. Furthermore, the very low rate of mortality in patients without TOD, 2.0% in hypertensive patients and 3.1% in the whole cohort, highlights that TOD reflects a high burden of atherosclerosis and vascular damage in patients with ACS.
The main limitation of our study might be derived from the design of the study that could have ended in a non-representative cohort; patients were included only after discharge from coronary care unit, 3-7 days after the acute event, and therefore patients that died in the first 72 h of hospital stay could not be included. Nevertheless, the aim of this prospective study was to describe the predictive value of ABI and TOD in the first year after an ACS, and this should not be affected by the inclusion criteria. Moreover, the prevalence of TOD is similar to other studies. 7, 13, 15, [24] [25] [26] [27] The study protocol did not include the assessment of other TODs, such as albuminuria, pulse wave velocity or retinopathy, and therefore their possible role on prognosis could not be assessed. Ejection fraction was the only echocardiographic parameter clearly defined in the protocol and, therefore, LVH diagnosis by this technique was available in just a minority of cases and with heterogenic criteria; this limitation might have underpowered findings related to LVH.
The main conclusions of our study are that TOD is more prevalent in hypertensive patients with ACS and its presence and clustering predicts mortality and ischaemic events in the first year after hospital discharge.
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